Insight Molecular Diagnostics Inc.'s next confirmed earnings release is scheduled for November 16, 2026.
| Earnings Date | 11/16/2026 |
As of June 30, 2026, Insight Molecular Diagnostics Inc. has 32.62M shares outstanding.
| Shares Outstanding | 32.62M |
As of June 30, 2026, Insight Molecular Diagnostics Inc. maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.32, indicating conservative leverage, while an interest coverage ratio of -488.32 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.00 |
| Quick Ratio | 1.74 |
| Debt / Equity | -12.32 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | -488.32 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -123.46, reflecting losses generated across the asset base. The company generates approximately 26,219.75 in revenue per employee across its workforce of 55.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.92 indicates how many times Insight Molecular Diagnostics Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -123.46 |
| Revenue Per Employee | 26,219.75 |
| Employee Count | 55.75 |
| Inventory Turnover | 1.92 |
As of the close on November 17, 2026, Insight Molecular Diagnostics Inc.'s stock has declined approximately 47.04% over the past 52 weeks. The 50-day moving average sits at 2.61, while the 200-day moving average is 2.67.
| 52-Week Price Change | -47.04% |
| 50-Day Moving Average | 2.61 |
| 200-Day Moving Average | 2.67 |
Over the twelve months ended June 30, 2026, Insight Molecular Diagnostics Inc. generated 1.46M in revenue and converted that into -43.20M in net income, yielding earnings per share of -1.28. EBITDA reached -41.89M, while operating income came in at -32.42M.
| Revenue | 1.46M |
| Gross Profit | 706,367.10 |
| Operating Income | -32.42M |
| Pretax Income | -43.20M |
| Net Income | -43.20M |
| EBITDA | -41.89M |
| EBIT | -44.03M |
| Earnings Per Share (EPS) | -1.28 |
As of June 30, 2026, Insight Molecular Diagnostics Inc. holds 15.54M in cash and equivalents against 2.30M in total debt, resulting in a net debt position of -15.54M. Total book value stands at -18.64M, with working capital of 8.98M providing operational flexibility.
| Cash & Cash Equivalents | 15.54M |
| Total Debt | 2.30M |
| Net Debt | -15.54M |
| Equity (Book Value) | -18.64M |
| Book Value Per Share | -0.57 |
| Working Capital | 8.98M |
Insight Molecular Diagnostics Inc. produced -23.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.43M in capital expenditures, free cash flow totaled -27.13M - equivalent to -0.80 per share.
| Operating Cash Flow | -23.70M |
| Capital Expenditures | -3.43M |
| Free Cash Flow | -27.13M |
| FCF Per Share | -0.80 |
Over the twelve months ended June 30, 2026, Insight Molecular Diagnostics Inc. posted a gross margin of 48.32, reflecting its pricing power and cost economics. The operating margin of -2,217.90 and net profit margin of -2,955.63 provide insight into operational efficiency.
| Gross Margin | 48.32 |
| Operating Margin | -2,217.90 |
| Pretax Margin | -2,955.63 |
| Profit Margin | -2,955.63 |
| EBITDA Margin | -2,865.57 |
Insight Molecular Diagnostics Inc.'s most recent stock split took place on July 25, 2023 with a 20:1 split ratio.
| Last Split Date | 7/25/2023 |
| Split Ratio | 20:1 |